Evolving First-Line Treatment in Advanced Renal Cell Carcinoma

Dr. Voss and Dr. Serzan discuss the evolution of first-line treatment patterns in advanced renal cell carcinoma (RCC) over the past several years, highlighting the transition from tyrosine kinase inhibitor monotherapy toward immune-based combination regimens. Drawing on recent real-world treatment-pattern data presented at KCRS, Dr. Voss notes the increasing adoption of upfront immuno-oncology approaches in clinical practice and the declining use of tyrosine kinase inhibitor monotherapy. The experts reflect on how advances in first-line therapy, together with the availability of subsequent treatment options, have contributed to substantial improvements in overall survival for patients with advanced RCC. The discussion then returns to the importance of the initial treatment decision and evolving goals of care. Dr. Voss emphasizes the aspiration for durable remission and, in a subset of patients, potentially curative outcomes, underscoring how advances in combination therapy have changed expectations for patients beginning treatment for advanced RCC.